Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $6.55, but opened at $6.36. Valneva shares last traded at $6.42, with a volume of 2,303 shares changing hands.
Wall Street Analyst Weigh In
A number of research firms recently commented on VALN. Guggenheim dropped their target price on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Valneva in a research report on Tuesday, April 15th.
Get Our Latest Stock Analysis on VALN
Valneva Price Performance
The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. The stock has a market capitalization of $543.73 million, a PE ratio of -5.37 and a beta of 1.74. The stock's 50-day moving average is $6.10 and its 200 day moving average is $6.27.
Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.27. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. The company had revenue of $51.79 million for the quarter, compared to the consensus estimate of $41.80 million. As a group, equities analysts expect that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.
Hedge Funds Weigh In On Valneva
An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN boosted its stake in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 as of its most recent filing with the SEC. 11.39% of the stock is owned by hedge funds and other institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
